2002
DOI: 10.1097/00004714-200208000-00008
|View full text |Cite
|
Sign up to set email alerts
|

Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine

Abstract: In a previous study, of 41 depressed patients who had not responded to fluoxetine 20 mg/day, 53% were treated with high-dose fluoxetine (40-60 mg/ day) and responded (i.e., their 17-item Hamilton Rating Scale for Depression [HAM-D-17] score was <7) versus 29% and 25% of patients treated with fluoxetine plus lithium (300-600 mg/day) or fluoxetine plus desipramine (25-50 mg/day), respectively. We wanted to assess whether these findings could be replicated in a larger sample of depressed outpatients. We identifie… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
79
1
2

Year Published

2003
2003
2022
2022

Publication Types

Select...
8
2

Relationship

2
8

Authors

Journals

citations
Cited by 119 publications
(86 citation statements)
references
References 36 publications
4
79
1
2
Order By: Relevance
“…1). [17][18][19][20][21][22][23][24][25][26][27][28] All 12 of these studies had obtained ethical approval. Altogether, the 12 studies included 1 936 patients and seven kinds of augmentation agents, namely lithium, tricyclic antidepressants (TCAs), atypical antipsychotics (AAPs), antiepileptic drugs (AEDs), buspirone, cognitive behaviour therapy (CBT) and tri-iodothyronine (T3).…”
Section: Resultsmentioning
confidence: 99%
“…1). [17][18][19][20][21][22][23][24][25][26][27][28] All 12 of these studies had obtained ethical approval. Altogether, the 12 studies included 1 936 patients and seven kinds of augmentation agents, namely lithium, tricyclic antidepressants (TCAs), atypical antipsychotics (AAPs), antiepileptic drugs (AEDs), buspirone, cognitive behaviour therapy (CBT) and tri-iodothyronine (T3).…”
Section: Resultsmentioning
confidence: 99%
“…Although it may seem counterintuitive, there is no convincing evidence of a dose response or therapeutic window with SSRIs and SNRIs, with the possible exception of venlafaxine [reviewed in (11 ); a small number of studies do support dose increase as a strategy in initial treatment nonresponders (12 )]. At the extremes, blood concentrations likely matter a great deal.…”
Section: Pharmacokinetic Variationmentioning
confidence: 99%
“…Osser: Dr. Fava, you conducted 2 studies 18,19 in which you augmented fluoxetine with desipramine or lithium or increased the dose of fluoxetine. In both of those studies, the results were relatively unimpressive for the augmentation with lithium.…”
Section: Dr Trivedimentioning
confidence: 99%